135P A multicenter retrospective observation study about overall survival benefit of eribulin mesylate in comparison with taxane regimens for metastatic cancer patients

Annals of Oncology ◽

10.1016/s0923-7534(21)00293-3 ◽

2016 ◽

Vol 27 ◽

pp. ix40

Author(s):

Y. Kikuchi ◽

Y. Uchida ◽

H. Kanauchi ◽

T. Niwa ◽

K. Nishioka ◽

...

Keyword(s):

Overall Survival ◽

Cancer Patients ◽

Survival Benefit ◽

Metastatic Cancer ◽

Observation Study ◽

Eribulin Mesylate ◽

Overall Survival Benefit

Download Full-text

135P A multicenter retrospective observation study about overall survival benefit of eribulin mesylate in comparison with taxane regimens for metastatic cancer patients

Annals of Oncology ◽

10.1093/annonc/mdw577.018 ◽

2016 ◽

Vol 27 (suppl_9) ◽

Author(s):

Y. Kikuchi ◽

Y. Uchida ◽

H. Kanauchi ◽

T. Niwa ◽

K. Nishioka ◽

...

Keyword(s):

Overall Survival ◽

Cancer Patients ◽

Survival Benefit ◽

Metastatic Cancer ◽

Observation Study ◽

Eribulin Mesylate ◽

Overall Survival Benefit

Download Full-text

Association of decrease of left ventricular ejection fraction with overall survival benefit in trastuzumab treated metastatic esogastric cancer patients.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.e15514 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. e15514-e15514

Author(s):

Jerome Martin-Babau ◽

Yves Eusen ◽

Laurent Doucet ◽

Helene Simon ◽

Elisabeth Gaye ◽

...

Keyword(s):

Overall Survival ◽

Left Ventricular Ejection Fraction ◽

Ejection Fraction ◽

Cancer Patients ◽

Survival Benefit ◽

Left Ventricular ◽

Ventricular Ejection ◽

Left Ventricular Ejection ◽

Ventricular Ejection Fraction ◽

Overall Survival Benefit

Download Full-text

A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience

Breast Cancer Research and Treatment ◽

10.1007/s10549-020-05626-1 ◽

2020 ◽

Vol 181 (1) ◽

pp. 211-220 ◽

Author(s):

J. Watanabe ◽

M. Saito ◽

Y. Horimoto ◽

S. Nakamoto

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Advanced Breast Cancer ◽

Cancer Patients ◽

Lymphocyte Count ◽

Survival Benefit ◽

Absolute Lymphocyte Count ◽

Breast Cancer Patients ◽

Institutional Experience ◽

Overall Survival Benefit

Download Full-text

Faculty Opinions recommendation of Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717969441.793468990 ◽

2013 ◽

Author(s):

Steven Le Gouill ◽

Cyrille Touzeau

Keyword(s):

Multiple Myeloma ◽

Overall Survival ◽

Survival Benefit ◽

Second Malignancies ◽

Increased Risk ◽

Overall Survival Benefit

Download Full-text

Faculty Opinions recommendation of Surgical resection provides an overall survival benefit for patients with small pancreatic neuroendocrine tumors.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727546585.793531209 ◽

2017 ◽

Author(s):

Christos Dervenis ◽

Dionysia Kelgiorgi

Keyword(s):

Overall Survival ◽

Surgical Resection ◽

Neuroendocrine Tumors ◽

Survival Benefit ◽

Pancreatic Neuroendocrine Tumors ◽

Overall Survival Benefit

Download Full-text

Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer

JAMA Oncology ◽

10.1001/jamaoncol.2020.1513 ◽

2020 ◽

Vol 6 (7) ◽

pp. 1121

Author(s):

Ryan Sun ◽

Dae Hyun Kim ◽

Lee-Jen Wei

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Hormone Receptor ◽

Survival Benefit ◽

Hormone Receptor Positive ◽

Overall Survival Benefit

Download Full-text

Longer follow-up of randomized trials on adjuvant radiotherapy for breast cancer stresses the overall survival benefit due to radiotherapy

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/s0360-3016(01)02025-9 ◽

2001 ◽

Vol 51 (3) ◽

pp. 109-110 ◽

Author(s):

J. Van de Steene ◽

V. Vinh-Hung ◽

G. Storme

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Adjuvant Radiotherapy ◽

Survival Benefit ◽

Randomized Trials ◽

Overall Survival Benefit

Download Full-text

Novel Calculator to Estimate Overall Survival Benefit from Neoadjuvant Chemoradiation in Patients with Esophageal Adenocarcinoma

Journal of the American College of Surgeons ◽

10.1016/j.jamcollsurg.2017.01.043 ◽

2017 ◽

Vol 224 (5) ◽

pp. 884-894.e1 ◽

Author(s):

Emmanuel Gabriel ◽

Kristopher Attwood ◽

Rupen Shah ◽

Steven Nurkin ◽

Steven Hochwald ◽

...

Keyword(s):

Overall Survival ◽

Esophageal Adenocarcinoma ◽

Survival Benefit ◽

Neoadjuvant Chemoradiation ◽

Overall Survival Benefit

Download Full-text

PO54 A RETROSPECTIVE MULTICENTER OBSERVATION STUDY IN METASTATIC BREAST CANCER PATIENTS: COMPARATIVE ANALYSIS ON EFFICACY OF ERIBULIN MESYLATE WITH TAXANE REGIMENS (INCLUDING COMBINATION WITH BEVACIZUMAB)

10.1016/s0960-9776(15)30066-7 ◽

2015 ◽

Vol 24 ◽

pp. S40

Author(s):

Yasuko Kikuchi ◽

Kazuo Shirakawa ◽

Hajime Kanauchi ◽

Takako Wakeda ◽

Takayoshi Niwa ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Comparative Analysis ◽

Cancer Patients ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Observation Study ◽

Eribulin Mesylate

Download Full-text

Abstract P3-14-24: Overall Survival Benefit Observed with Lapatinib (L) Plus Paclitaxel (P) as First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer (MBC)

10.1158/0008-5472.sabcs10-p3-14-24 ◽

2010 ◽

Author(s):

Z-z Guan ◽

B-h Xu ◽

W Arpornwirat ◽

Z-s Tong ◽

V Lorvidhaya ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast Cancer ◽

Survival Benefit ◽

Metastatic Breast ◽

First Line Therapy ◽

Line Therapy ◽

Overall Survival Benefit

Download Full-text